Ownership and insider activity for CalciMedica, Inc. (CALC): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions.
Price
| Price | $1.98 |
| Market Cap | $6M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.8M | $15.9M | $33.4M | $13.4M | $1.3M | $5.5M | $7.9M | $11.5M |
| Short-term Investments | 0 | $20.1M | $61.6M | $50.3M | 0 | $5.7M | $10.7M | $1.5M |
| Receivables | 0 | 0 | 0 | $21000 | $39000 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | -$21000 | 0 | 0 | 0 | 0 |
| Total Current Assets | $13.4M | $36.3M | $99.2M | $67.1M | $1.7M | $11.6M | $19.7M | $13.5M |
| Property, Plant & Equipment | $1.5M | $2.0M | $1.9M | $2.0M | $195000 | $167000 | $119000 | $50000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $17.8M | $40.7M | $101.8M | $69.1M | $3.3M | $12.2M | $19.8M | $13.6M |
| Accounts Payable | $2.5M | $4.6M | $2.5M | $527000 | $2.9M | $1.4M | $2.0M | $1.2M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.2M |
| Total Current Liabilities | $5.8M | $12.3M | $7.0M | $4.1M | $4.8M | $4.0M | $3.7M | $3.8M |
| Long-term Debt | 0 | 0 | 0 | 0 | $5.2M | 0 | 0 | $8.4M |
| Total Liabilities | $5.8M | $12.3M | $7.0M | $4.1M | $12.6M | $4.0M | $5.4M | $20.2M |
| Retained Earnings | -$68.8M | -$105.8M | -$133.4M | -$169.2M | -$111.7M | -$146.1M | -$159.8M | -$189.3M |
| Total Equity | $12.0M | $28.4M | $94.8M | $65.0M | -$9.2M | $8.2M | $14.4M | -$6.6M |
| Total Debt | $78.8M | $131.4M | 0 | 0 | $5.4M | 0 | 0 | $9.7M |
| Net Debt | $66.0M | $95.4M | -$95.0M | -$63.7M | $4.0M | -$11.2M | -$18.7M | -$3.3M |
| Working Capital | $7.7M | $24.0M | $92.2M | $63.0M | -$3.0M | $7.6M | $16.0M | $9.7M |
Financial Health
| Debt / Equity | -1.46 |
| Current Ratio | 3.58 |
Profitability
| Return on Equity | 445.14% |
| Return on Invested Capital | -209.07% |
| Return on Assets | -217.51% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ATNM · ELUT · LTRN · LVTX · MAIA · PDSB · RNXT
Explore sector: Healthcare · Biotechnology
More sections of CALC: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks